

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/12	A1	(11) International Publication Number: WO 98/05302 (43) International Publication Date: 12 February 1998 (12.02.98)
(21) International Application Number: PCT/GB97/01502 (22) International Filing Date: 3 June 1997 (03.06.97) (30) Priority Data: 9616237.5 1 August 1996 (01.08.96) GB (71) Applicant (for all designated States except US): NORTON HEALTHCARE LIMITED [GB/GB]; Gemini House, Flex Meadow, Harlow, Essex CM29 5TJ (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): MILLER, Fiona [GB/GB]; Norton Healthcare Limited, Gemini House, Flex Meadow, Harlow, Essex CM29 5TJ (GB). (74) Agent: PAWLYN, Anthony, Neil; Urquhart-Dykes & Lord, Tower House, Merriion Way, Leeds LS2 8PA (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GI, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: AEROSOL FORMULATIONS (57) Abstract The replacement of chlorofluorohydrocarbon propellants in medical aerosols is of the utmost importance to the pharmaceutical industry. A number of formulations have been investigated. The present invention provides a medical aerosol formulation comprising a particular medicament, a fluorocarbon propellant and 6 to 25 % w/w of the total formulation of a polar co-solvent, such formulation being substantially free of surfactant. Cannisters suitable for delivering such a pharmaceutical formulation are also provided.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

AEROSOL FORMULATIONS

This invention relates to pharmaceutical formulations for inhalation aerosols. The Montreal Protocol on ozone depleting gases has made the reformulation of existing pharmaceutical aerosols for inhalation treatment containing chlorofluorohydrocarbon propellants, a matter of urgency for the pharmaceutical industry.

A number of hydrofluorocarbons (HFCs) have been the subject to toxicological testing and two in particular P134a (1,1,1,2-tetrafluoroethane) and P227 (1,1,1,2,3,3,3-heptafluoropropane) have been identified as safe for use in pharmaceutical aerosols.

A number of patent applications have been submitted in this field, the first being EP 372777, which discloses the use of four component mixtures, comprising a medicament, a surfactant, P134a and a co-solvent of higher polarity than the P134a, in the form of a solution or a suspension.

As inhalation aerosols are meant for administration to the lung, it has long been accepted that such formulations should contain as few ingredients as possible, to avoid putting unnecessary materials into the lung.

Historically, despite EP 372777, solution aerosols contained only medicament, propellant or propellant mixtures and, if necessary, co-solvent, usually ethanol, eg US 2868691. The use of a surfactant was normally unnecessary for solution aerosols. However, historically medicinal suspension aerosols have contained a surfactant eg US 3014844, as it was considered that the use of a surfactant was necessary to prevent agglomeration of particles, to prevent adhesion to the sides of the canister, and to aid valve lubrication and prevent valve sticking.

However it was disclosed in EP 616525 that it is possible to prepare medicament suspensions in a hydrofluorocarbon without the need for a surfactant, if a polar co-solvent was added. The normal co-solvent ethanol, has well established

-2-

physiological actions and being a pure absorbable liquid eliminates any possibility of residues remaining in the lung. Irritation or possible toxicity from the surfactant, many of which are mixtures of similar compounds, are avoided.

EP 616525 specifically limits the polar co-solvent level to 0.01 to 5% w/w and in particular states (page 3, line 55) that the preferred level is about 0.1% w/w.

According to a first aspect of the present invention there is provided a medicinal aerosol formulation comprising a particulate medicament, a fluorocarbon propellant and 6% to 25% w/w of the total formulation of a polar co-solvent, such formulation being substantially free of surfactant.

According to a second aspect of the present invention there is provided a medicinal aerosol formulation, comprising one or more particulate medicaments, one or more fluorocarbon or hydrocarbon or aliphatic gas propellants and 6% to 25% w/w of a polar co-solvent.

According to a third aspect of the present invention there is provided a canister suitable for delivering a pharmaceutical aerosol formulation, which comprises a container capable of withstanding the vapour pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which comprises particulate medicament, a propellant consisting all or part of fluorocarbon and 6% to 25% of a polar co-solvent, which is substantially free of surfactant.

It has now been surprisingly found that higher levels of alcohol have beneficial results. Levels of 6% or more of ethanol produce satisfactory suspensions, which do not agglomerate on standing, and on reshaking produce finely dispersed medicament. It is believed that the higher levels of alcohol reduce the degree of deposition on the inside of the can. This is a very desirable feature. In addition, the use of these larger percentages of ethanol enables a much cheaper production process.

Medicinal aerosols can be filled either with one dose of liquid containing all of the ingredients mixed together or by

-3-

a two dose process where the first dose contains the medicament and all other ingredients, including co-solvents, surfactants, if any, ancillary compounds eg flavours, if any, and some times some of the propellant followed by a second dose of pure propellant. This two dose fill has major cost advantages in that the volume of mix for a fixed number of cans is significantly smaller enabling the use of smaller mixing vessels. In particular, with the use of the new HFC propellants, which have lower boiling points than the old CFC propellants, the use of a one dose fill may involve the use of cooled pressurised vessels to prevent evaporation of the propellant gas during mixing and filling. With the new formulations with added extra co-solvent a first mix of just medicament suspended in the co-solvent can be used, followed by a second dose of pure propellant. This means that the propellant can be dosed directly from a holding tank into the can without any need to mix and store with the other ingredients. For example a mix weight of 1g of medicament and co-solvent can be followed by 7.5g of propellant. In this way the volume to be mixed is reduced from 8.5g to 1g. All the examples in EP 616525 are of laboratory scale, where the handling problems are much easier, but all the formulations described are such that it would not be practicable to fill in two doses without mixing the propellant, as is the case with the present disclosure.

The description of the filling method given on page 5 lines 2-13 indicates that only a one dose filling method is envisaged.

In all cases of the present invention the medicament consists of a particle size suitable for inhalation into the lung and will thus be less than 100 microns, desirably less than 20 microns and preferably in the range of 1-10 microns, normally with a mean particle size 1-5 microns.

Medicaments which may be administered in aerosol formulations according to the invention include any drug useful in inhalation therapy which may be presented in a form which is substantially completely insoluble in the selected propellant.

-4-

Appropriate medicaments may thus be selected from, for example, analgesics, eg codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, eg diltiazem; antiallergics, eg cromoglycate, ketotifen or nedocromil; anti-infectives, eg cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, eg methapyrilene; anti-inflammatories, eg beclomethasone, flunisolide, budesonide, tipredane, triamcinolone acetonide or fluticasone; antitussives, eg noscapine; bronchodilators, eg ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, salbutamol, salmeterol, terbutaline, isoetharine, tolubuterol, orciprenaline; diuretics, eg amiloride; anticholinergics, eg ipratropium, atropine or oxitropium; hormones, eg cortisone, hydrocortisone or prednisolone; xanthines, eg aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; and therapeutic proteins and peptides, eg insulin or glucagon. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts (eg as alkali metal or amine salts or as acid addition salts) or as esters (eg lower alkyl esters) or as solvates (eg hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the propellant.

Preferred are those compounds which are also substantially insoluble in the co-solvent. Particularly preferred as medicament is salbutamol either as base or as a salt and especially salbutamol sulphate.

Co-solvents may be selected from polar alcohols and polyols, particularly C₂-C₆ aliphatic alcohols and polyols, such as propylene glycol, and preferably ethanol. Levels of co-solvent will be between 6% and 25% w/w of the total canister content, preferably between 10-15% w/w of canister content.

The propellant may be a hydrofluorocarbon, particularly P134a or P227. Other hydrofluorocarbons or hydrocarbons or aliphatic gases (eg Dimethylether) may be added to modify the

-5-

propellant characteristics as required.

The product is preferentially produced by weighing the active medicament and suspending it in the co-solvent. The appropriate amount of suspension is then dosed into the can, followed by a second dose of propellant or propellant mix. However, a one shot fill or any other equivalent method may be employed.

The normal medicinal product on the market has an actuator with spray orifice diameter of about 480 microns. However, with the larger percentages of ethanol envisaged in this invention, it is desirable that the co-solvent evaporates from the particles as rapidly as possible.

This is achieved by reducing the aperture to between 100-300 microns, which for the same dosage or drug, gives more rapid evaporation of the co-solvent. A particularly preferred embodiment of the invention is a combination of a level 10-15% co-solvent (normally ethanol) with a stem aperture of 150-250 microns.

The invention is further described by means of example but not in any limitative sense.

Example

Salbutamol Sulphate	0.03g
Ethanol	0.97g
Tetrafluoroethane (P134a)	7.5g

The salbutamol sulphate previously micronised to give over 90% of particles below 10 microns was weighed out and added to the ethanol. The suspension was mixed until it was smooth and uniform and then filled into the aerosol canister. The metering valve assembly was crimped (preferably vacuum crimped) on the canister and then the P134a was filled through the valve. The valve capacity is such as to deliver 100 micrograms of salbutamol, as salbutamol sulphate per actuation.

A particularly preferred use of such a canister is in a patient breath operated device rather than the normal hand

-6-

operated device. Such devices are available commercially such as those under the trade mark "Easi-Breathe".

-7-

Claims:

1. A medicinal aerosol formulation comprising a particulate medicament, a fluorocarbon propellant and 6% to 25% w/w of the total formulation of a polar co-solvent, such formulation being substantially free of surfactant.
2. A medicinal aerosol formulation, comprising one or more particulate medicaments, one or more fluorocarbon or hydrocarbon or aliphatic gas propellants and 6% to 25% w/w of a polar co-solvent.
3. A formulation as claimed in claim 1 or claim 2, wherein the medicament is an anti-allergic, a bronchodilator or an anti-inflammatory steroid.
4. A formulation as claimed in claim 3, where the medicament is ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropandamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, orciprenaline, salbutamol, salmeterol, sodium cromoglycate, fluticasone, beclomethasone or similar molecule and any physiologically acceptable salt, solvate or ester of such compound.
5. A formulation, as claimed in claims 1-3, where the medicament is a salt of salbutamol.
6. A formulation, as claimed in claims 1-3, where the medicament is a salt of formoterol (sometimes called eformoterol).
7. A formulation according to any of claims 1 to 5, wherein the propellant is 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n-propane.
8. A formulation according to any of claims 1 to 5,

-8-

where the co-solvent level is 10-15%.

9. A formulation according to any of claims 1-5, wherein the polar co-solvent is ethanol.

10. A canister suitable for delivering a pharmaceutical aerosol formulation, which comprises a container capable of withstanding the vapour pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which comprises particulate medicament, a propellant consisting all or part of fluorocarbon and 6% to 25% of a polar co-solvent, which is substantially free of surfactant.

11. A canister according to claim 9, fitted into an adaptor with an aperture of 100-300 microns.

12. A product according to claims 9 and 10 where the medicament is as per claim 4.

13. A product according to claims 9-11, where the medicament is a salt of salbutamol.

14. A product according to claims 9-11, where the medicament is a salt of formoterol.

15. A canister according to claims 9 and 10, which is actuated by a breath operated device.

16. A product according to claim 15, where the medicament is a salt of salbutamol.

17. A product according to claim 15, where the medicament is a salt of formoterol.

INTERNATIONAL SEARCH REPORT

Intern. Application No. PCT/GB 97/01502

A. CLASSIFICATION OF SUBJECT MATTER

A 61 K 9/12

According to International Patent Classification (IPC) or to both national classification and IPC ⁶

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO, A, 93/11 745 (GLAXO GROUP LIMITED) 24 June 1993 (24.06.93), abstract; claims 1-15. --	1-5, 7-10
A	WO, A, 93/11 743 (GLAXO GROUP LIMITED) 24 June 1993 (24.06.93), abstract; claims 1-21. --	1-5, 7-10
A	WO, A, 94/03 153 (GLAXO GROUP LIMITED) 17 February 1994 (17.02.94), abstract; claims 1-12. --	1-5, 7-10
A	WO, A, 94/13 262 (JAGER et al.) 23 June 1994 (23.06.94), abstract; claims 1-38,	1-5, 7-9

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search
03 September 1997

Date of mailing of the international search report

26.09.97

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentaan 2
NL - 2280 JJ Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

SCHNASS e.h.

INTERNATIONAL SEARCH REPORT

-2-

International Application No
PCT/GB 97/01502

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	<p>especially claim 4.</p> <p>-----</p>	

ANHANG

zum internationalen Recherchen-
bericht über die internationale
Patentanmeldung Nr.

ANNEX

to the International Search
Report to the International Patent
Application No.

ANNEXE

au rapport de recherche inter-
national relatif à la demande de brevet
international n°

PCT/GB 97/01502 SAE 162218

In diesem Anhang sind die Mitglieder
der Patentfamilien der in obenge-
nannten internationalen Recherchenbericht
angeführten Patentedokumente angegeben.
Diese Angaben dienen nur zur Unter-
richtung und erfolgen ohne Gewähr.

This Annex lists the patent family
members relating to the patent documents
cited in the above-mentioned inter-
national search report. The Office is
in no way liable for these particulars
which are given merely for the purpose
of information.

La présente annexe indique les
membres de la famille de brevets
relatifs aux documents de brevets cités
dans le rapport de recherche inter-
national visé ci-dessus. Les renseigne-
ments fournis sont donnés à titre indica-
tif et n'engagent pas la responsabilité
de l'Office.

In Recherchenbericht angeführtes Patentedokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WO A1 9311745		AP AO 9200461 AF A 4002 AT E 1283500 AU A1 0850790 AU A1 0851179 AU A1 0852790 AU A1 0853490 AU A1 0854190 AU A1 0854890 AU A1 0855590 AU A1 0856290 AU A1 0856990 AU A1 0857690 AU A1 0858390 AU A1 0859090 AU A1 0859790 AU A1 0860490 AU A1 0861190 AU A1 0861890 AU A1 0862590 AU A1 0863290 AU A1 0863990 AU A1 0864690 AU A1 0865390 AU A1 0866090 AU A1 0866790 AU A1 0867490 AU A1 0868190 AU A1 0868890 AU A1 0869590 AU A1 0870290 AU A1 0870990 AU A1 0871690 AU A1 0872390 AU A1 0873090 AU A1 0873790 AU A1 0874490 AU A1 0875190 AU A1 0875890 AU A1 0876590 AU A1 0877290 AU A1 0877990 AU A1 0878690 AU A1 0879390 AU A1 0880090 AU A1 0880790 AU A1 0881490 AU A1 0882190 AU A1 0882890 AU A1 0883590 AU A1 0884290 AU A1 0884990 AU A1 0885690 AU A1 0886390 AU A1 0887090 AU A1 0887790 AU A1 0888490 AU A1 0889190 AU A1 0889890 AU A1 0890590 AU A1 0891290 AU A1 0891990 AU A1 0892690 AU A1 0893390 AU A1 0894090 AU A1 0894790 AU A1 0895490 AU A1 0896190 AU A1 0896890 AU A1 0897590 AU A1 0898290 AU A1 0898990 AU A1 0899690 AU A1 0900390 AU A1 0901090 AU A1 0901790 AU A1 0902490 AU A1 0903190 AU A1 0903890 AU A1 0904590 AU A1 0905290 AU A1 0905990 AU A1 0906690 AU A1 0907390 AU A1 0908090 AU A1 0908790 AU A1 0909490 AU A1 0910190 AU A1 0910890 AU A1 0911590 AU A1 0912290 AU A1 0912990 AU A1 0913690 AU A1 0914390 AU A1 0915090 AU A1 0915790 AU A1 0916490 AU A1 0917190 AU A1 0917890 AU A1 0918590 AU A1 0919290 AU A1 0919990 AU A1 0920690 AU A1 0921390 AU A1 0922090 AU A1 0922790 AU A1 0923490 AU A1 0924190 AU A1 0924890 AU A1 0925590 AU A1 0926290 AU A1 0926990 AU A1 0927690 AU A1 0928390 AU A1 0929090 AU A1 0929790 AU A1 0930490 AU A1 0931190 AU A1 0931890 AU A1 0932590 AU A1 0933290 AU A1 0933990 AU A1 0934690 AU A1 0935390 AU A1 0936090 AU A1 0936790 AU A1 0937490 AU A1 0938190 AU A1 0938890 AU A1 0939590 AU A1 0940290 AU A1 0940990 AU A1 0941690 AU A1 0942390 AU A1 0943090 AU A1 0943790 AU A1 0944490 AU A1 0945190 AU A1 0945890 AU A1 0946590 AU A1 0947290 AU A1 0947990 AU A1 0948690 AU A1 0949390 AU A1 0950090 AU A1 0950790 AU A1 0951490 AU A1 0952190 AU A1 0952890 AU A1 0953590 AU A1 0954290 AU A1 0954990 AU A1 0955690 AU A1 0956390 AU A1 0957090 AU A1 0957790 AU A1 0958490 AU A1 0959190 AU A1 0959890 AU A1 0960590 AU A1 0961290 AU A1 0961990 AU A1 0962690 AU A1 0963390 AU A1 0964090 AU A1 0964790 AU A1 0965490 AU A1 0966190 AU A1 0966890 AU A1 0967590 AU A1 0968290 AU A1 0968990 AU A1 0969690 AU A1 0970390 AU A1 0971090 AU A1 0971790 AU A1 0972490 AU A1 0973190 AU A1 0973890 AU A1 0974590 AU A1 0975290 AU A1 0975990 AU A1 0976690 AU A1 0977390 AU A1 0978090 AU A1 0978790 AU A1 0979490 AU A1 0980190 AU A1 0980890 AU A1 0981590 AU A1 0982290 AU A1 0982990 AU A1 0983690 AU A1 0984390 AU A1 0985090 AU A1 0985790 AU A1 0986490 AU A1 0987190 AU A1 0987890 AU A1 0988590 AU A1 0989290 AU A1 0989990 AU A1 0990690 AU A1 0991390 AU A1 0992090 AU A1 0992790 AU A1 0993490 AU A1 0994190 AU A1 0994890 AU A1 0995590 AU A1 0996290 AU A1 0996990 AU A1 0997690 AU A1 0998390 AU A1 0999090 AU A1 0999790 AU A1 1000490 AU A1 1001190 AU A1 1001890 AU A1 1002590 AU A1 1003290 AU A1 1003990 AU A1 1004690 AU A1 1005390 AU A1 1006090 AU A1 1006790 AU A1 1007490 AU A1 1008190 AU A1 1008890 AU A1 1009590 AU A1 1010290 AU A1 1010990 AU A1 1011690 AU A1 1012390 AU A1 1013090 AU A1 1013790 AU A1 1014490 AU A1 1015190 AU A1 1015890 AU A1 1016590 AU A1 1017290 AU A1 1017990 AU A1 1018690 AU A1 1019390 AU A1 1020090 AU A1 1020790 AU A1 1021490 AU A1 1022190 AU A1 1022890 AU A1 1023590 AU A1 1024290 AU A1 1024990 AU A1 1025690 AU A1 1026390 AU A1 1027090 AU A1 1027790 AU A1 1028490 AU A1 1029190 AU A1 1029890 AU A1 1030590 AU A1 1031290 AU A1 1031990 AU A1 1032690 AU A1 1033390 AU A1 1034090 AU A1 1034790 AU A1 1035490 AU A1 1036190 AU A1 1036890 AU A1 1037590 AU A1 1038290 AU A1 1038990 AU A1 1039690 AU A1 1040390 AU A1 1041090 AU A1 1041790 AU A1 1042490 AU A1 1043190 AU A1 1043890 AU A1 1044590 AU A1 1045290 AU A1 1045990 AU A1 1046690 AU A1 1047390 AU A1 1048090 AU A1 1048790 AU A1 1049490 AU A1 1050190 AU A1 1050890 AU A1 1051590 AU A1 1052290 AU A1 1052990 AU A1 1053690 AU A1 1054390 AU A1 1055090 AU A1 1055790 AU A1 1056490 AU A1 1057190 AU A1 1057890 AU A1 1058590 AU A1 1059290 AU A1 1059990 AU A1 1060690 AU A1 1061390 AU A1 1062090 AU A1 1062790 AU A1 1063490 AU A1 1064190 AU A1 1064890 AU A1 1065590 AU A1 1066290 AU A1 1066990 AU A1 1067690 AU A1 1068390 AU A1 1069090 AU A1 1069790 AU A1 1070490 AU A1 1071190 AU A1 1071890 AU A1 1072590 AU A1 1073290 AU A1 1073990 AU A1 1074690 AU A1 1075390 AU A1 1076090 AU A1 1076790 AU A1 1077490 AU A1 1078190 AU A1 1078890 AU A1 1079590 AU A1 1080290 AU A1 1080990 AU A1 1081690 AU A1 1082390 AU A1 1083090 AU A1 1083790 AU A1 1084490 AU A1 1085190 AU A1 1085890 AU A1 1086590 AU A1 1087290 AU A1 1087990 AU A1 1088690 AU A1 1089390 AU A1 1090090 AU A1 1090790 AU A1 1091490 AU A1 1092190 AU A1 1092890 AU A1 1093590 AU A1 1094290 AU A1 1094990 AU A1 1095690 AU A1 1096390 AU A1 1097090 AU A1 1097790 AU A1 1098490 AU A1 1099190 AU A1 1099890 AU A1 1100590 AU A1 1101290 AU A1 1101990 AU A1 1102690 AU A1 1103390 AU A1 1104090 AU A1 1104790 AU A1 1105490 AU A1 1106190 AU A1 1106890 AU A1 1107590 AU A1 1108290 AU A1 1108990 AU A1 1109690 AU A1 1110390 AU A1 1111090 AU A1 1111790 AU A1 1112490 AU A1 1113190 AU A1 1113890 AU A1 1114590 AU A1 1115290 AU A1 1115990 AU A1 1116690 AU A1 1117390 AU A1 1118090 AU A1 1118790 AU A1 1119490 AU A1 1120190 AU A1 1120890 AU A1 1121590 AU A1 1122290 AU A1 1122990 AU A1 1123690 AU A1 1124390 AU A1 1125090 AU A1 1125790 AU A1 1126490 AU A1 1127190 AU A1 1127890 AU A1 1128590 AU A1 1129290 AU A1 1129990 AU A1 1130690 AU A1 1131390 AU A1 1132090 AU A1 1132790 AU A1 1133490 AU A1 1134190 AU A1 1134890 AU A1 1135590 AU A1 1136290 AU A1 1136990 AU A1 1137690 AU A1 1138390 AU A1 1139090 AU A1 1139790 AU A1 1140490 AU A1 1141190 AU A1 1141890 AU A1 1142590 AU A1 1143290 AU A1 1143990 AU A1 1144690 AU A1 1145390 AU A1 1146090 AU A1 1146790 AU A1 1147490 AU A1 1148190 AU A1 1148890 AU A1 1149590 AU A1 1150290 AU A1 1150990 AU A1 1151690 AU A1 1152390 AU A1 1153090 AU A1 1153790 AU A1 1154490 AU A1 1155190 AU A1 1155890 AU A1 1156590 AU A1 1157290 AU A1 1157990 AU A1 1158690 AU A1 1159390 AU A1 1160090 AU A1 1160790 AU A1 1161490 AU A1 1162190 AU A1 1162890 AU A1 1163590 AU A1 1164290 AU A1 1164990 AU A1 1165690 AU A1 1166390 AU A1 1167090 AU A1 1167790 AU A1 1168490 AU A1 1169190 AU A1 1169890 AU A1 1170590 AU A1 1171290 AU A1 1171990 AU A1 1172690 AU A1 1173390 AU A1 1174090 AU A1 1174790 AU A1 1175490 AU A1 1176190 AU A1 1176890 AU A1 1177590 AU A1 1178290 AU A1 1178990 AU A1 1179690 AU A1 1180390 AU A1 1181090 AU A1 1181790 AU A1 1182490 AU A1 1183190 AU A1 1183890 AU A1 1184590 AU A1 1185290 AU A1 1185990 AU A1 1186690 AU A1 1187390 AU A1 1188090 AU A1 1188790 AU A1 1189490 AU A1 1190190 AU A1 1190890 AU A1 1191590 AU A1 1192290 AU A1 1192990 AU A1 1193690 AU A1 1194390 AU A1 1195090 AU A1 1195790 AU A1 1196490 AU A1 1197190 AU A1 1197890 AU A1 1198590 AU A1 1199290 AU A1 1199990 AU A1 1200690 AU A1 1201390 AU A1 1202090 AU A1 1202790 AU A1 1203490 AU A1 1204190 AU A1 1204890 AU A1 1205590 AU A1 1206290 AU A1 1206990 AU A1 1207690 AU A1 1208390 AU A1 1209090 AU A1 1209790 AU A1 1210490 AU A1 1211190 AU A1 1211890 AU A1 1212590 AU A1 1213290 AU A1 1213990 AU A1 1214690 AU A1 1215390 AU A1 1216090 AU A1 1216790 AU A1 1217490 AU A1 1218190 AU A1 1218890 AU A1 1219590 AU A1 1220290 AU A1 1220990 AU A1 1221690 AU A1 1222390 AU A1 1223090 AU A1 1223790 AU A1 1224490 AU A1 1225190 AU A1 1225890 AU A1 1226590 AU A1 1227290 AU A1 1227990 AU A1 1228690 AU A1 1229390 AU A1 1230090 AU A1 1230790 AU A1 1231490 AU A1 1232190 AU A1 1232890 AU A1 1233590 AU A1 1234290 AU A1 1234990 AU A1 1235690 AU A1 1236390 AU A1 1237090 AU A1 1237790 AU A1 1238490 AU A1 1239190 AU A1 1239890 AU A1 1240590 AU A1 1241290 AU A1 1241990 AU A1 1242690 AU A1 1243390 AU A1 1244090 AU A1 1244790 AU A1 1245490 AU A1 1246190 AU A1 1246890 AU A1 1247590 AU A1 1248290 AU A1 1248990 AU A1 1249690 AU A1 1250390 AU A1 1251090 AU A1 1251790 AU A1 1252490 AU A1 1253190 AU A1 1253890 AU A1 1254590 AU A1 1255290 AU A1 1255990 AU A1 1256690 AU A1 1257390 AU A1 1258090 AU A1 1258790 AU A1 1259490 AU A1 1260190 AU A1 1260890 AU A1 1261590 AU A1 1262290 AU A1 1262990 AU A1 1263690 AU A1 1264390 AU A1 1265090 AU A1 1265790 AU A1 1266490 AU A1 1267190 AU A1 1267890 AU A1 1268590 AU A1 1269290 AU A1 1269990 AU A1 1270690 AU A1 1271390 AU A1 1272090 AU A1 1272790 AU A1 1273490 AU A1 1274190 AU A1 1274890 AU A1 1275590 AU A1 1276290 AU A1 1276990 AU A1 1277690 AU A1 1278390 AU A1 1279090 AU A1 1279790 AU A1 1280490 AU A1 1281190 AU A1 1281890 AU A1 1282590 AU A1 1283290 AU A1 1283990 AU A1 1284690 AU A1 1285390 AU A1 1286090 AU A1 1286790 AU A1 1287490 AU A1 1288190 AU A1 1288890 AU A1 1289590 AU A1 1290290 AU A1 1290990 AU A1 1291690 AU A1 1292390 AU A1 1293090 AU A1 1293790 AU A1 1294490 AU A1 1295190 AU A1 1295890 AU A1 1296590 AU A1 1297290 AU A1 1297990 AU A1 1298690 AU A1 1299390 AU A1 1299990 AU A1 1300690 AU A1 1301390 AU A1 1302090 AU A1 1302790 AU A1 1303490 AU A1 1304190 AU A1 1304890 AU A1 1305590 AU A1 1306290 AU A1 1306990 AU A1 1307690 AU A1 1308390 AU A1 1309090 AU A1 1309790 AU A1 1310490 AU A1 1311190 AU A1 1311890 AU A1 1312590 AU A1 1313290 AU A1 1313990 AU A1 1314690 AU A1 1315390 AU A1 1316090 AU A1 1316790 AU A1 1317490 AU A1 1318190 AU A1 1318890 AU A1 1319590 AU A1 1320290 AU A1 1320990 AU A1 1321690 AU A1 1322390 AU A1 1323090 AU A1 1323790 AU A1 1324490 AU A1 1325190 AU A1 1325890 AU A1 1326590 AU A1 1327290 AU A1 1327990 AU A1 1328690 AU A1 1329390 AU A1 1330090 AU A1 1330790 AU A1 1331490 AU A1 1332190 AU A1 1332890 AU A1 1333590 AU A1 1334290 AU A1 1334990 AU A1 1335690 AU A1 1336390 AU A1 1337090 AU A1 1337790 AU A1 1338490 AU A1 1339190 AU A1 1339890 AU A1 1340590 AU A1 1341290 AU A1 1341990 AU A1 1342690 AU A1 1343390 AU A1 1344090 AU A1 1344790 AU A1 1345490 AU A1 1346190 AU A1 1346890 AU A1 1347590 AU A1 1348290 AU A1 1348990 AU A1 1349690 AU A1 1350390 AU A1 1351090 AU A1 1351790 AU A1 1352490 AU A1 1353190 AU A1 1353890 AU A1 1354590 AU A1 1355290 AU A1 1355990 AU A1 1356690 AU A1 1357390 AU A1 1358090 AU A1 1358790 AU A1 1359490 AU A1 1360190 AU A1 1360890 AU A1 1361590 AU A1 1362290 AU A1 1362990 AU A1 1363690 AU A1 1364390 AU A1 1365090 AU A1 1365790 AU A1 1366490 AU A1 1367190 AU A1 1367890 AU A1 1368590 AU A1 1369290 AU A1 1369990 AU A1 1370690 AU A1 1371390 AU A1 1372090 AU A1 1372790 AU A1 1373490 AU A1 1374190 AU A1 1374890 AU A1 1375590 AU A1 1376290 AU A1 1376990 AU A1 1377690 AU A1 1378390 AU A1 1379090 AU A1 1379790 AU A1 1380490 AU A1 1381190 AU A1 1381890 AU A1 1382590 AU A1 1383290 AU A1 1383990 AU A1 1384690 AU A1 1385390 AU A1 1386090 AU A1 1386790 AU A1 1387490 AU A1 1388190 AU A1 1388890 AU A1 1389590 AU A1 1390290 AU A1 1390990 AU A1 1391690 AU A1 1392390 AU A1 1393090 AU A1 1393790 AU A1 1394490 AU A1 1395190 AU A1 1395890 AU A1 1396590 AU A1 1397290 AU A1 1397990 AU A1 1398690 AU A1 1399390 AU A1 1399990 AU A1 1400690 AU A1 1401390 AU A1 1402090 AU A1 1402790 AU A1 1403490 AU A1 1404190 AU A1 1404890 AU A1 1405590 AU A1 1406290 AU A1 1406990 AU A1 1407690 AU A1 1408390 AU A1 1409090 AU A1 1409790 AU A1 1410490 AU A1 1411190 AU A1 1411890 AU A1 1412590 AU A1 1413290 AU A1 1413990 AU A1 1414690 AU A1 1415390 AU A1 1416090 AU A1 1416790 AU A1 1417490 AU A1 1418190 AU A1 1418890 AU A1 1419590 AU A1 1420290 AU A1 1420990 AU A1 1421690 AU A1 1422390 AU A1 1423090 AU A1 1423790 AU A1 1424490 AU A1 1425190 AU A1 1425890 AU A1 1426590 AU A1 1427290 AU A1 1427990 AU A1 1428690 AU A1 1429390 AU A1 1430090 AU A1 1430790 AU A1 1431490 AU A1 1432190 AU A1 1432890 AU A1 1433590 AU A1 1434290 AU A1 1434990 AU A1 1435690 AU A1 1436390 AU A1 1437090 AU A1 1437790 AU A1 1438490 AU A1 1439190 AU A1 1439890 AU A1 1440590 AU A1 1441290 AU A1 1441990 AU A1 1442690 AU A1 1443390 AU A1 1444090 AU A1 1444790 AU A1 1445490 AU A1 1446190 AU A1 1446890 AU A1 1447590 AU A1 1448290 AU A1 1448990 AU A1 1449690 AU A1 1450390 AU A1 1451090 AU A1 1451790 AU A1 1452490 AU A1 1453190 AU A1 1453890 AU A1 1454590 AU A1 1455290 AU A1 1455990 AU A1 1456690 AU A1 145739	

[illegible]